Immunome (IMNM) recently reported dosing the first patient in a Phase 1 trial of IM-3050, a fibroblast activation protein targeted radioligand therapy, a pipeline milestone that often attracts fresh investor attention.

At a share price of $25.69, Immunome has seen a 23.39% year to date share price return and a very large 1 year total shareholder return. This may indicate that momentum has been building around recent pipeline updates and changing expectations for future outcomes.

If you are tracking how biotech sentiment is shifting after Immunome's latest trial news, it can be useful to compare it with other specialized companies through 43 healthcare AI stocks

For Immunome, the sharp one year move and recent trial milestone could reflect a stronger view of the pipeline, or it could be mostly sentiment chasing new headlines. The valuation section next helps frame that trade off.

Preferred Price to Book Ratio of 4.9x: Is it justified?

Immunome is currently valued at a P/B of 4.9x, which sits between its direct peers and the broader US biotech industry. That split picture is what investors need to unpack.

The P/B ratio compares a company’s share price with its book value per share. For a development stage biotech like Immunome that reports limited revenue of $4.0m and a net loss of $224.6m, P/B is often used as a rough gauge of how the market prices the pipeline and balance sheet relative to accounting equity.

Compared with the US Biotechs industry average P/B of 2.5x, Immunome trades at almost double that level. That implies the market is assigning a richer valuation than the broader group. However, relative to a peer set trading on an average P/B of 9.2x, Immunome sits at a discount. This contrast suggests investors are paying up versus the sector overall but not as much as for closer peers that the model groups together on size and profile. See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 4.9x (ABOUT RIGHT)

However, investors still face clear risks if Immunome’s clinical trials disappoint or if ongoing net losses of $224.6m raise future funding and dilution questions.

Another View on Immunome using our DCF model

The earlier P/B discussion presented Immunome as somewhere between the wider biotech sector and its closer peers. Our DCF model presents a very different picture. With the share price at $25.69 and an estimated future cash flow value of $176.27, the stock appears heavily undervalued on this measure.

For investors, that gap raises a straightforward question. Is the market discounting Immunome’s clinical and funding risks too harshly, or is the DCF model being too optimistic about what this pipeline can ultimately deliver to shareholders

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Immunome for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With both risks and rewards in play for Immunome, it makes sense to move quickly and review the underlying data yourself before sentiment shifts again. To weigh the clinical, financial and valuation issues side by side, start with the 3 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Immunome?

If you want to broaden your watchlist beyond Immunome, now is a good time to scan for other stocks that fit clear, data driven criteria before the crowd catches on.

• Target potential mispricings by checking stocks that combine strong fundamentals with attractive valuations through the 51 high quality undervalued stocks.
• Prioritize resilience by reviewing companies that appear on the 83 resilient stocks with low risk scores, where lower risk scores help you focus your research time.
• Spot underfollowed opportunities early by scanning the screener containing 21 high quality undiscovered gems, which highlights fundamentally solid businesses that many investors may still be overlooking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.